Drugs like semaglutide, the active ingredient of Ozempic and Wegovy, are more effective in treating type 2 diabetes than ...

A large McGill University study has found that two classes of medications commonly prescribed for Type 2 diabetes, both ...

A McGill University study of more than 450,000 patients found that incretin-based Type 2 diabetes drugs, including GLP-1 ...

A large McGill University study has found that two classes of medications commonly prescribed for Type 2 diabetes, both ...

The research has generated significant interest from firms in food & supplements as consumers seek natural alternatives to ...

Objective: DPP-4 inhibitors are now established agents for glycaemic control in diabetes. Herein, this study systematically characterized cofrogliptin and elucidated its pharmacology, pharmacokinetics ...

Type 2 diabetes occurs when the body does not use insulin effectively or does not produce enough insulin to maintain healthy blood sugar levels. Medications aim to lower blood glucose, reduce A1C, and ...

The initiation of GLP-1 agonists was associated with a lower risk for Alzheimer’s disease and related dementias than the initiation of DPP-4 inhibitors in patients with diabetes undergoing ...

Biologics, including GLP-1 analogs and PCSK9 inhibitors, are advancing treatment options for metabolic syndrome components like type 2 diabetes and dyslipidemia. GLP-1 receptor agonists improve ...

In patients with type 2 diabetes (T2D), dual therapy with metformin and GLP-1 receptor agonists (RAs) was associated with a 39% lower risk for adiposity-related cancers and a 67% lower risk for ...